Illimis Therapeutics
Korea - SeoulBiotechnology
Focus: Illimis Therapeutics is an early-stage Korean biotech focused on biologics based on a chimeric fusion protein platform. Founded in 2022, the company is currently in Series B funding with pre-revenue status.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
SERIES B
Open Jobs
0
About Illimis Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Illimis Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2022
Publications:
Help build intelligence for Illimis Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.